<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02112968</url>
  </required_header>
  <id_info>
    <org_study_id>1302</org_study_id>
    <nct_id>NCT02112968</nct_id>
  </id_info>
  <brief_title>A Prospective Safety and Effectiveness Study of a New High Repetition Rate Excimer Laser Using LASIK for the Correction of Ammetropia and Presbyopia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technolas Perfect Vision GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technolas Perfect Vision GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study has been planned to evaluate the safety and effectiveness of common&#xD;
      treatment algorithms using 500 Hz laser repetition rate for the correction of Ammetropia and&#xD;
      Presbyopia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study has been planned to evaluate the safety and effectiveness of the excimer&#xD;
      laser treatment algorithms Proscan, Zyoptix and Supracor of the 500 Hz laser system for&#xD;
      ametropia and/or presbyopia when performed on the cornea of virgin eyes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For Proscan and Zyoptix: - The percentage of treated eyes within +/- 0.50D of target refraction. For Supracor: - The percentage of treated eyes with a best corrected high contrast distance VA of Snellen 20/25 (6/7.5 or 0.1 logMAR) or better</measure>
    <time_frame>Myopia: 6 months, Hyperopia 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Myopia</condition>
  <condition>Hyperopia</condition>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Proscan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ametropia Lasik treatment of virgin eyes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zyoptix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wavefront based ametropia Lasik treatment of virgin eyes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supracor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ametropia Lasik treatment of virgin eyes with presbyopia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Proscan</intervention_name>
    <description>One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)</description>
    <arm_group_label>Proscan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Zyoptix</intervention_name>
    <description>One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)</description>
    <arm_group_label>Zyoptix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Supracor</intervention_name>
    <description>One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)</description>
    <arm_group_label>Supracor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects have to be at least 18 years of age.&#xD;
&#xD;
          -  Subjects have to be able to read, understand, and sign a statement of Informed Consent&#xD;
             (be given a copy of the signed Informed Consent Form (ICF).&#xD;
&#xD;
          -  Subjects have to be willing and able to return for scheduled follow-up examinations&#xD;
             for up to 6 respectively 12 months after surgery.&#xD;
&#xD;
          -  For Proscan and Zyoptix Treatments the myopic subjects require a sphere between -0.5 D&#xD;
             up to a maximum sphere of -10.0 D. If the patient has a refractive astigmatism to be&#xD;
             treated, this must be between -0.5 D up to -4.0 D (not corneal astigmatism) as&#xD;
             expressed in spectacle minus cylinder form (by manifest subjective refraction).&#xD;
             Overall the SE for myopes must be no more than -12.0 D.&#xD;
&#xD;
          -  The Hyperopic subjects require a sphere between +0.5 D up to a maximum sphere of +4.0&#xD;
             D. If the patient has a refractive astigmatism to be treated, this must be between&#xD;
             +0.5 D up to +4.0 D (not corneal astigmatism) as expressed in spectacle plus cylinder&#xD;
             form (by manifest subjective refraction). Overall the SE for hyperopes must be no more&#xD;
             than +6.0 D.&#xD;
&#xD;
          -  Subjects who are contact lens wearers must have gas permeable lenses discontinued for&#xD;
             at least 3 weeks and soft lenses discontinued for at least 1 week prior to the&#xD;
             pre-operative evaluation in the eye to be treated.&#xD;
&#xD;
          -  Corneal topography should be qualified.&#xD;
&#xD;
          -  Subjects who are contact lens wearers must have two (2) central keratometry readings&#xD;
             and two (2) manifest subjective refractions taken pre-operatively at least one week&#xD;
             apart. The refraction values must not differ by more than 0.50 D as defined by&#xD;
             manifest refraction spherical equivalent (MRSE). The keratometry values must not&#xD;
             differ from the previous values by more than 0.50 D in either meridian.&#xD;
&#xD;
          -  High contrast, manifest, best spectacle-corrected distance visual acuity correctable&#xD;
             binocular to at least 1.0 (Snellen 20/20 or 6/6) and monocular to at least 0.8&#xD;
             (Snel-len 20/25 or 6/7.5). In case of a monocular surgery the eye which should not be&#xD;
             treated must have a best corrected distance visual acuity of at least 0.8 (Snellen&#xD;
             20/25 or 6/7.5).&#xD;
&#xD;
          -  For treatments with the SUPRACOR presbyopic algorithm, subjects have to be at least 45&#xD;
             years old and no more than 85 years.&#xD;
&#xD;
          -  For treatments with the SUPRACOR presbyopic algorithm, subjects must have presbyopia&#xD;
             as determined by an age-related need for optical aid (&gt; +1.50 D) for reading with&#xD;
             their best distance correction and been screened successfully for acceptance of the&#xD;
             SUPRACOR simulation.&#xD;
&#xD;
          -  For treatments with the SUPRACOR presbyopic algorithm, subjects must been screened&#xD;
             successfully for acceptance of the SUPRACOR simulation&#xD;
&#xD;
          -  For treatments with the SUPRACOR presbyopic algorithm, Myopic subjects must have up to&#xD;
             -7.0 diopters (D) of absolute spherical myopia (not spherical equivalent), with up to&#xD;
             -4.0 D of refractive astigmatism (NOT corneal astigmatism) by manifest subjective&#xD;
             refraction. The spherical equivalent and must be no more than -9.0 D.&#xD;
&#xD;
          -  Hyperopic subjects must have up to +4 diopters (D) of absolute spherical hyperopia&#xD;
             (not spherical equivalent), with up to +2.5 D of refractive astigmatism (NOT corneal&#xD;
             astigmatism) by manifest subjective refraction in both eyes. The spherical equivalent&#xD;
             must be no more than +5.25 D.&#xD;
&#xD;
          -  Mesopic pupil size measured with the Zywave II WaveFront Aberrometer must be &lt; 7.0 mm&#xD;
             and photopic pupil size measured with the Orbscan II/ IIz must be &gt; 2.9 mm.&#xD;
&#xD;
          -  For treatments with the Zyoptix algorithm, the high-order-aberration must be at least&#xD;
             0.35µm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects for whom the combination of their baseline corneal thickness and the planned&#xD;
             operative parameters for the LASIK procedure would result in less than 250 microns of&#xD;
             remaining posterior corneal thickness below the flap postoperatively.&#xD;
&#xD;
          -  Hyperopic eyes for which the baseline manifest subjective refraction exhibits a&#xD;
             difference of greater than ± 0.75 D in sphere power, or a difference of greater than ±&#xD;
             0.50 D in cylinder power, or a difference in cylinder axis of more than 15 degrees&#xD;
             compared to the baseline cycloplegic subjective refraction. For manifest cylinder of&#xD;
             less than ±0.75 D, the difference in cylinder axis would not be taken into&#xD;
             consideration.&#xD;
&#xD;
          -  Any subject who is going to be co-managed by an ophthalmologist or optometrist who&#xD;
             were not approved as a Technolas Perfect Vision Investigator.&#xD;
&#xD;
          -  Subjects with anterior segment pathology, including dry eye syndrome and cataracts,&#xD;
             which in the Investigator's opinion would interfere with best spectacle-corrected&#xD;
             visual acuity or a successful treatment.&#xD;
&#xD;
          -  Subjects with evidence of retinal vascular disease.&#xD;
&#xD;
          -  Subjects with any residual, recurrent, or active ocular disease, or corneal&#xD;
             abnormality that in the Investigator's opinion would interfere with BSCVA or a&#xD;
             successful treatment.&#xD;
&#xD;
          -  Subjects with signs of keratoconus.&#xD;
&#xD;
          -  Subjects with unstable central keratometry readings with irregular mires.&#xD;
&#xD;
          -  Subjects who had previous intraocular or corneal surgery of any kind, including any&#xD;
             type of Excimer laser surgery for either refractive or therapeutic purposes.&#xD;
&#xD;
          -  Subjects who have a history of Herpes simplex or Herpes zoster keratitis.&#xD;
&#xD;
          -  Subject who have a history of glaucoma or glaucoma suspect.&#xD;
&#xD;
          -  Subjects with corneal edema, or increased IOP &gt; 22mmHg.&#xD;
&#xD;
          -  Subjects at risk for angle closure.&#xD;
&#xD;
          -  Subjects immunocompromised or carrying diagnosis of connective tissue disease,&#xD;
             clinically significant atopic disease, diabetes, autoimmune diseases and other acute&#xD;
             or chronic illnesses that will increase the risk to the subject or confound the&#xD;
             outcomes of this study.&#xD;
&#xD;
          -  Subject taking systemic medications likely to affect wound healing such as&#xD;
             corticosteroids or antimetabolites.&#xD;
&#xD;
          -  Subjects who are known to be pregnant, lactating, or who plans to become pregnant over&#xD;
             the course of the study.&#xD;
&#xD;
          -  Subjects with known sensitivity to medications used for standard LASIK.&#xD;
&#xD;
          -  Subjects participating in any other ophthalmic clinical trials during this clinical&#xD;
             study.&#xD;
&#xD;
          -  Subjects with an ocular muscle disorder including a strabismus or nystagmus, or other&#xD;
             disorders affecting fixation.&#xD;
&#xD;
          -  Subjects with cognitive impairments or other vulnerable persons.&#xD;
&#xD;
          -  Subjects with anterior or posterior synechiae.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavel Stodulka, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gemini ocni centrum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanie Doerner</last_name>
    <phone>+49 89 94004130</phone>
    <email>melanie.doerner@bausch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patrick Schmidt</last_name>
    <phone>+49 89 94004391</phone>
    <email>patrick.schmidt@bausch.com</email>
  </overall_contact_backup>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>April 10, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <last_update_submitted>November 19, 2014</last_update_submitted>
  <last_update_submitted_qc>November 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myopia</keyword>
  <keyword>Hyperopia</keyword>
  <keyword>Presbyopia</keyword>
  <keyword>Supracor</keyword>
  <keyword>Zyoptix</keyword>
  <keyword>Proscan</keyword>
  <keyword>LASIK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Presbyopia</mesh_term>
    <mesh_term>Hyperopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

